CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

Thomas Lingelbach

Chief Executive Officer, Valneva

Search every verified Thomas Lingelbach interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. At Valneva's 2026 Annual General Meeting, Thomas Lingelbach, the company's CEO, addressed shareholders regarding the progress of the company's Lyme disease vaccine program, developed in partnership with Pfizer. Lingelbach described the program as "the single largest catalyst for Valneva" and "the single largest value driver," but noted that "the market unfortunately has completely written off its value." He also commented on a statistical miss in the vaccine's study results, stating that "the statistical miss doesn't mean that the vaccine does not work" and that "the vaccine works, the vaccine is efficacious," attributing the miss to the confidence interval in the study. During the meeting, Lingelbach and other executives presented Valneva's financial results, including a revenue increase attributed to the partnership with Pfizer for the Lyme vaccine and the launch of a production unit in Scotland. Research and development expenses rose due to exchange rates, while marketing and distribution costs decreased following a 2024 efficiency program. Shareholders voted on several resolutions, including the rejection of one resolution and the adoption of others, such as an amendment to the company's articles of association.

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →